Immix Biopharma develops CAR T cell therapies, led by NXC-201, for AL amyloidosis and other serious diseases. It last closed at $6.96 on Nov 20, down 1.14% on the day. The next earnings report for IMMX is expected around Thu, Feb 11, 2027, after the close. For the quarter ended Sep 2026, IMMX reported EPS of -$0.19. Over the last 12 months IMMX insiders bought $30K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is IMMX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IMMX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on IMMXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
IMMX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 12% below its 20 day and 33% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $6.74, and the nearest resistance the Pivot at $7.12.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 8.7%/day
Key levels
$15.1052 week high+117.0%
$10.23100 day average+47.0%
$9.64200 day average+38.5%
$9.2550 day average+32.9%
$8.36Swing high (Oct 29)+20.1%
$7.7720 day average+11.6%
$7.34Pivot R1+5.5%
$7.12Pivot+2.3%
$6.96Last close
$6.74Pivot S1−3.2%
$3.7852 week low−45.7%
Indicators
RSI (14)
35.51
Weak, oversold below 30
Neutral
MACD
-0.53
Below its signal line
Bearish
Stochastic
3.6
Near the bottom of its range
Oversold
ADX (14)
32.6
Trending down
Williams %R
-97.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-123.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−13.7%
Change over 10 sessions
Bearish
ATR (14)
$0.60
Typical daily range, 8.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 21.6%/day
Key levels
$15.1052 week high+117.0%
$10.23100 day average+47.0%
$9.64200 day average+38.5%
$9.2550 day average+32.9%
$8.36Swing high (Oct 29)+20.1%
$7.7720 day average+11.6%
$7.34Pivot R1+5.5%
$7.12Pivot+2.3%
$6.96Last close
$6.74Pivot S1−3.2%
$3.7852 week low−45.7%
Indicators
RSI (14)
38.46
Weak, oversold below 30
Neutral
MACD
-0.39
Below its signal line
Bearish
Stochastic
7.2
Near the bottom of its range
Oversold
ADX (14)
22.9
Weak trend
Williams %R
-99.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-110.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−42.7%
Change over 10 sessions
Bearish
ATR (14)
$1.51
Typical daily range, 21.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for IMMX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IMMX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow IMMX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for IMMXHow many large options trades hit IMMX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in IMMX in the last 90 days.
From SEC Form 4 filings by IMMX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMMX is in one of them and how their past IMMX trades turned out.
Immix Biopharma is a biopharmaceutical company based in Los Angeles, California. It develops chimeric antigen receptor (CAR) T cell therapies, led by its candidate NXC-201, for AL amyloidosis, a serious disease in which an abnormal protein builds up in organs such as the heart and kidneys. The lead candidate is in clinical trials and is not yet approved for sale. The company's target patients have this disease or other serious conditions where CAR T therapy is not yet an approved treatment.